Verisante Technology, Inc.
TSX VENTURE : VRS
OTCQX : VRSEF
FRANKFURT : V3T

Verisante Technology, Inc.

November 08, 2013 13:53 ET

Verisante Technology, Inc. Closes Prospectus Offering

To Be Featured on Business Television (BTV)

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 8, 2013) - Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(FRANKFURT:V3T) (the "Company" or "Verisante"), a leader in cancer detection technology, today announced closing of its previously announced commercially reasonably efforts public offering of units ("Units") pursuant to a short form base shelf prospectus (the "Offering"). The Offering was conducted by Jordan Capital Markets Inc. (the "Agent"). Each Unit was priced at $0.19 and consisted of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant"). Each Warrant is exercisable to acquire one Common Share at a price of $0.25 until November 8, 2015, subject to certain acceleration provisions contained within the warrant certificate.

Pursuant to the Offering, the Company issued 5,546,316 Units for gross proceeds of $1,053,800. In consideration for the services of the Agent in connection with the Offering, the Company paid a cash commission equal to approximately 9% of the gross proceeds of the Offering, and issued Agents Warrants to acquire up to an aggregate of 504,152 common shares exercisable at a price of $0.25 per common share until November 8, 2015, subject to certain acceleration provisions contained within the warrant certificate. The Company also paid the Agent a corporate finance fee.

The Company intends to use the net proceeds of the Offering to conduct a sales marketing campaign for Aura™, to further develop and refine Aura™, to finance manufacturing of Aura™ devices, to pursue regulatory approval in the United States, and to cover general and administrative costs.

This press release is not an offer to sell or the solicitation of an offer to buy the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements.

Feature on Business Television

Verisante also announced today that the Company will be featured on Business Television (BTV) on November 9-17, 2013. BTV, a half-hour business program, has been profiling innovative companies in North America every week for the past 14 years. Verisante will air on BTV on the following channels:

In Canada

  • BNN - Sunday, November 10, 2013 @ 9:30am & 8:00pm EST
  • Bell Express Vu - Sunday, November 10, 2013 @ 9:30am & 8:00pm EST

In the United States

  • Fox Business News - Sunday, November 10, 2013 @ 5:30pm EST
  • America One - Saturday, November 9, 2013 @ 10am EST
  • Biz Television Network - Monday, November 11, 2013 @ 8:30am EST, Thursday, November 14, 2013 @ 10:30am EST and Friday, November 15, 2013 @ 10pm & 1am EST, Saturday, November 16, 2013 @ 12pm & 8pm, Sunday, November 17 @ 12:30pm EST

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. Core™ has not yet been approved for sale.

Verisante Aura™ was awarded Popular Science Magazine's "Best of What's New Award" for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an Edison Award for Excellence in Innovation in 2013. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

Contact Information